Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
Top 4 Health Care Stocks That May Keep You Up At Night
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Johnson & Johnson (JNJ)
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 Mg/Vial Due To The Presence Of A Glass Particle
Express News | FDA: Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for Injection 100 Mg/Vial Due to the Presence of a Glass Particle
Yuhan Signs KRW107.7 Billion Deal With Gilead Sciences for HIV Treatment Raw Material Supply
Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In. -- Barrons.com
Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
Gilead Sciences Unusual Options Activity For September 20
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings